Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study.
Cappiello
A
A
Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT 06519, USA.
McDougle
C J
CJ
Malison
R T
RT
Heninger
G R
GR
Price
L H
LH
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy* / Q000523:psychology; D004351:Drug Resistance; D004357:Drug Synergism; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D016037:Single-Blind Method; D015016:Yohimbine / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D018687:Antidepressive Agents, Second-Generation; D015016:Yohimbine; D016666:Fluvoxamine